Literature DB >> 15207542

Degradation of raw or film-incorporated beta-cyclodextrin by enzymes and colonic bacteria.

Axel Fetzner1, Stefan Böhm, Sven Schreder, Rolf Schubert.   

Abstract

beta-cyclodextrin (beta-CD) is a suitable excipient for peroral use, which improves the solubility of lipophilic drugs, as well as for colon-specific drug release when it is mixed with coating polymers. The first aim of this work was to examine the suitability of various enzymes as a simple in vitro model for the glycolytic activity in the human colon. alpha-Amylase (source Aspergillus oryzae) and taka diastase (source A. oryzae) showed remarkable degradation capacity of free beta-CD, whereas other alpha-amylases (sources Bacillus subtilis or Hog pancreas) were found to be unsuitable. The next aim was to find out if film-incorporated beta-CD is also degraded by these enzymes. Therefore, diffusion studies of 5-aminosalicylic acid (5-ASA) through Eudragit RS or Eudragit NE films containing beta-CD were performed with taka diastase present in the buffer medium. Pronounced diffusion of the drug through the Eudragit RS film was found only when swelling excipients like crosslinked sodium carboxymethylcellulose (CMC-CL sodium) or polyvinylpyrrolidone (PVP 25) were present in the film, indicating enhanced accessibility of beta-CD by the enzyme. Films containing CMC-CL without beta-CD showed even higher permeability, which also points to enzymatic degradation of CMC-CL. Permeabilization by taka diastase of Eudragit NE films without swelling agents correlated with the beta-CD content, whereas control films containing talcum remained impermeable upon enzyme action. Furthermore, the beta-CD degradation capacity of colonic bacteria like Escherichia fergusonii, Serratia odorifera or Proteus mirabilis was examined with beta-CD coatings on tablets, which contained bisoprolol as a model drug. Tablets with beta-CD-containing Eudragit RS coatings showed the highest drug release upon incubation with P. mirabilis. The moderate drug release by E. fergusonii could be increased almost to the same level when the bacteria were pre-incubated for 24 h in medium containing 2.5 mg/ml beta-CD, indicating the induction of glycolytic enzymes by beta-CD in this colonic bacteria strain. Copyright 2004 Elsevier B.V.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15207542     DOI: 10.1016/j.ejpb.2004.02.001

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  6 in total

1.  Effects of commonly used excipients on the expression of CYP3A4 in colon and liver cells.

Authors:  Leslie Tompkins; Caitlin Lynch; Sam Haidar; James Polli; Hongbing Wang
Journal:  Pharm Res       Date:  2010-05-26       Impact factor: 4.200

2.  β-Cyclodextrin-hemin complex-induced lateral root formation in tomato: involvement of nitric oxide and heme oxygenase 1.

Authors:  Jiale Li; Dan Zhu; Ren Wang; Wenbiao Shen; Yingying Guo; Yong Ren; Wei Shen; Liqin Huang
Journal:  Plant Cell Rep       Date:  2014-11-30       Impact factor: 4.570

3.  Sugar-Grafted Cyclodextrin Nanocarrier as a "Trojan Horse" for Potentiating Antibiotic Activity.

Authors:  Min Li; Koon Gee Neoh; Liqun Xu; Liang Yuan; David Tai Leong; En-Tang Kang; Kim Lee Chua; Li Yang Hsu
Journal:  Pharm Res       Date:  2016-01-20       Impact factor: 4.200

4.  A novel dissolution media for testing drug release from a nanostructured polysaccharide-based colon specific drug delivery system: an approach to alternative colon media.

Authors:  Niranjan G Kotla; Sima Singh; Balaji Maddiboyina; Omprakash Sunnapu; Thomas J Webster
Journal:  Int J Nanomedicine       Date:  2016-03-17

5.  Nitric oxide diffusion through cystic fibrosis-relevant media and lung tissue.

Authors:  Jackson R Hall; Sara E Maloney; Haibao Jin; James B Taylor; Mark H Schoenfisch
Journal:  RSC Adv       Date:  2019-12-04       Impact factor: 4.036

6.  Designed construction of tween 60@2β-CD self-assembly vesicles as drug delivery carrier for cancer chemotherapy.

Authors:  Yue Yuan; Qin Zhang; Yun Yan; Miaomiao Gong; Qi Zhao; Zhihong Bao; Kaerdun Liu; Siling Wang
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.